158 results about "Tetrahydrocannabinol" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the KCNT1 gene. The CBD used is in the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w / w). In an alternative embodiment the CBD may be in a synthetic form. In use the CBD may also be used concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention discloses a hyperbranched anion exchange magnetic solid-phase extraction adsorbent as well as a preparation method and application thereof. The adsorbent Fe3O4 (at) poly (GMA / DVB-WAX) is obtained by carrying out hyperbranched anion modification on Fe3O4 (at) poly (GMA / DVB) microspheres through ethylenediamine and 1, 4-butanediol glycidyl ether. Compared with an Oasis MCX adsorbent and an Oasis HLB adsorbent, the adsorbent provided by the invention has better extraction efficiency. Compared with a column type solid-phase extraction method, the magnetic solid-phase extraction method provided by the invention has the advantages that the sample can be directly extracted without being filtered, the pretreatment step is simplified, and the sensitivity of the method is improved. The invention also establishes a magnetic solid phase extraction-ultra-high performance liquid chromatography-mass spectrometry (MSPE-UHPLC-MS / MS) method for determining four cannabinoids, namely tetrahydrocannabinol, cannabidiol, cannabinol and tetrahydrocannabinoic acid, in the sewage, and the method has the advantages of short pretreatment time, simplicity and convenience in operation, sensitivity and accuracy, and can be used for detecting the four cannabinoids, namely the tetrahydrocannabinol, the cannabidiol, the cannabinol and the tetrahydrocannabinoic acid in the sewage. The trace analysis of the four cannabinoids in the sewage can be met, and the method has very high practicability.

The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternatively, a synthetically produced THCV is used.

Vaporizer pods for use with a vaporizer configured to generate vapor from dry herbs, and the vaporizer pods comprising reconstituted tobacco and very low THC reconstituted cannabis.

The invention discloses a graft modification type magnetic MOF adsorbent, a preparation method thereof and cannabinoid detection application. The adsorbent is prepared by carrying out a ring-opening reaction on amino of 1-(3-aminopropyl) imidazole and epoxy, modifying a large number of imidazole functional groups on the surface of a Fe3O4 (at) poly (GMA / DVB) microsphere, and carrying out a self-assembly reaction on amino imidazole on the surface of the microsphere, zinc salt ZnCl2 and 2-methylimidazole on the surface of the microsphere, and is a magnetic MOF material Fe3O4 (at) poly (GMA / DVB-ZIF-8) with a large number of ZIF-8 crystals on the surface. The magnetic solid-phase extraction adsorbent is applied to extraction and purification of four cannabinoids including tetrahydrocannabinol, cannabidiol, cannabinol and tetrahydrocannabinoic acid in urine or saliva, and has excellent selectivity and adsorption performance. Compared with other pretreatment technologies, the magnetic solid phase extraction and ultra-high performance liquid chromatography-mass spectrometry combined method does not need complex steps such as nitrogen blowing, the pretreatment time is greatly shortened, the recovery rate is high, the extraction efficiency is high, and the practicability is very high.

In one aspect, the disclosure relates to new cannabidiol (CBD) analogs produced from allylic monoterpene alcohols and substituted resorcinols in the presence of aryl boronic acids, efficient and mild synthetic methods of making the new CBD analogs, and improved methods of making known CBD analogs. In one aspect, the methods produce low amounts of tetrahydrocannabinol (THC)-like compounds, low amounts of abnormal cannabidiol (abn-CBD) analogs, and higher amounts of CBD analogs, greatly simplifying purification. The methods can be tailored further to produce low amounts of CBD analogs and higher amounts abn-CBD analogs. In the disclosed methods, synthesis parameters can be varied in order to selectively produce a desired normal or abnormal regioisomer.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

Provided are methods, devices, and systems for identifying the concentration of delta-9-tetrahydrocannabinol (Δ-9 THC) in a given sample. The system allows for in situ formation of a chromophore eliminating the use of chloroform, wherein said chromophore absorbance spectra is measured using a spectroscopy method within a light wavelength range. The system allows for calculating the concentration of Δ-9 THC using the linear relationship between the Δ-9 THC level and the intensity of the color change in the present tester. Said linear relationship is obtained because the tester of the present disclosure allows the chromophore formation reaction go to completion.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with Lennox-Gastaut syndrome (LGS) who are deemed to be treatment failures on their existing medication. In particular the use of CBD was found to provide a statistically significant reduction in both drop seizures and total seizure frequency in patients who have tried and failed anti-epileptic drugs (AEDs) or those who were currently taking AEDs but have uncontrolled seizures. Preferably the AEDs which have been shown to be treatment failures are one or more of rufinamide, lamotrigine, topiramate and / or felbamate. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.

A method is for use with a treatment regime that includes the exposure of a patient to THC. The method comprises the step of administering Theanine to the patient. The Theanine can be L-Theanine. The treatment regime can involve a plurality of administrations of THC and Theanine can be administered with each administration of THC. The method of administration can be such that the peak bioavailability of THC occurs substantially contemporaneously with the peak bioavailability of Theanine. A consumer package can be adapted for carrying out the method.

The invention discloses a method for determining the content of forbidden substances in electronic cigarette liquid. The method specifically comprises the following steps: (1) pre-treating a sample; (2) carrying out LC-MS / MS analysis conditions; and (3) determining a standard curve and quantifying. Based on the LC-MS / MS technology, the content of taurine, caffeine, cannabidiol (CBD), tetrahydrocannabinol (THC), vitamin E and vitamin E acetate in the electronic cigarette liquid can be measured at the same time, and therefore the requirements for industry supervision, product quality control and safety evaluation are met.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment. Such CBD preparations are characterized by chemical components and / or functional properties that distinguish them from prior CBD compositions. One or more components of the preparations described herein provide an unexpectedly synergistic effect when utilized in combination.

The present invention relates to novel cannabinoids 1 and 2 synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization, and further cyclization that is highly stereoselective and regioselective for tetracyclic cannabinoids. The synthesized cannabinoids can be obtained more easily at a higher purity level than cannabinoids isolated or synthesized by known methods. Cannabinoid 2 is obtained containing very low levels of unwanted isomer cannabinoids, such as Δ8-tetrahydrocannabinol. While they are easily synthesized by the new methodology, analogs with modifications of aromatic ring substituents would be much more difficult to produce from any of the components of cannabis oil. Novel compounds of formulas 3, 4, 5, and 6 are disclosed as intermediates for the synthesis of cannabinoids of formulas 1 and 2.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking caffeine. Where the CBD is used in combination with caffeine, caution should be taken. For example, the dose of either the CBD and / or caffeine may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

In one aspect, the disclosure relates to the use of negative allosteric modulators (NAMs) of cannabinoid receptor 1 (CB1) and pharmaceutical compositions comprising the same in methods of treating or preventing diseases or disorders including substance abuse, anxiety, pain, obesity, cancers, neurodegenerative disorders, and central nervous system (CNS) disorders. In one aspect, the NAM can be selected from H4-CBD or CBDP. In some aspects, the pharmaceutical compositions additionally include Δ9-tetrahydrocannabinol (THC), and the NAMs of CB1 reduce or eliminate unwanted neurological side effects of THC while preserving its disease- and symptom-mitigating effects.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure may broadly provide composition for applying to food comprising a cannabidiol (CBD) having a purity greater than 90% and a tetrahydrocannabinol (THC) having a purity greater than 90% at a ratio of CBD:THC of about 5:1 to about 80:1, for a combined cannabinoid concentration of up to 15 g / L, a pharmaceutically compatible carrier oil, a pharmaceutically compatible emulsifier system, greater than 60% w / v water, and the composition having a viscosity of 500 to 5,000 cP at 21°C, a pH of between 4-7 and being in the form of an oil-in-water nanoemulsion.

The present disclosure relates to the transdermal administration of tetrahydrocannabinol (THC) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

This invention provides methods for the synthesis of cannabidiol and its analogues, as well as related compounds, formulations, and methods of use. [Solution] Methods are provided for the synthesis of oliveitol, oliveitol analogs, cannabidiol (CBD), CBD analogs, and other cannabinoids. One method uses phloroglucinol or phloroglucinol analogs as starting materials. The synthesis is stereospecific, efficient, selective, cost-effective, and THC((-)-trans-Δ 9 There is little to no possibility of generating (tetrahydro-cannabinol) or any other psychoactive by-products. Shortened synthesis is also provided, as well as new cannabinoids, pharmaceutical formulations, and methods of use.

The embodiment of the invention belongs to the technical field of detection, and relates to a detection reagent of delta 9-tetrahydrocannabinol and a preparation method and a detection method thereof, the detection reagent comprises a first detection reagent and a second detection reagent, and the preparation method comprises the following steps: dissolving NaCl in a buffer solution to obtain the first detection reagent; and dissolving the bovine serum albumin-anti-delta9-tetrahydrocannabinol antibody immobilized latex microspheres in a buffer solution to obtain the second detection reagent. The detection accuracy is improved.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

Provided are methods, devices, and systems for identifying the concentration of delta-9-tetrahydrocannabinol (Δ-9 THC) in a given sample. The system allows for in situ formation of a chromophore eliminating the use of chloroform, wherein said chromophore absorbance spectra is measured using a spectroscopy method within a light wavelength range. The system allows for calculating the concentration of Δ-9 THC using the linear relationship between the Δ-9 THC level and the intensity of the color change in the present tester. Said linear relationship is obtained because the tester of the present disclosure allows the chromophore formation reaction go to completion.

Compositions comprising 0.1 to 50% delta-9-tetrahydrocannabinol and / or cannabidiol, the forms of which are suitable for continuous delivery, and their use in the treatment of various diseases and pathological conditions are disclosed. In a preferred embodiment, the composition is in a form suitable for delivery by a portable infusion pump or transdermal patch. The conditions to be treated include pain, cancer, seizure conditions, and Parkinson's disease. The composition may optionally further comprise an additional active agent, such as a dopaminergic agent, depending on the condition to be treated.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.